The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Characterization of retatrutide in research settings relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase separation resolves the parent peptide from related impurities, while electrospray ionization mass spectrometry confirms molecular mass against a calculated value. Peptide mapping after enzymatic digestion can verify the amino acid sequence. Laboratories often combine orthogonal methods because no single technique establishes both identity and purity. Detected impurities typically include truncated sequences, oxidized residues, and deamidated forms that arise during synthesis or storage.
Material handling focuses on limiting degradation. Lyophilized powder is generally stored at reduced temperature, often around minus twenty degrees Celsius, protected from light and moisture. Once dissolved, the peptide is less stable and is commonly kept cold and used within a short window. Repeated freeze-thaw cycles promote aggregation and should be avoided. Buffers and pH influence stability, and solution conditions are usually selected to keep the peptide near neutral pH where degradation proceeds more slowly. These practices apply to laboratory reference material, not to clinical preparations.
Verification of research-grade material depends on documentation supplied with a sample. A certificate of analysis lists purity, identity, and the methods used to establish each value. Buyers comparing suppliers look at chromatographic purity figures, mass confirmation data, and whether methods are described in enough detail to be reproduced. Independent testing can confirm reported values but adds cost and time. Because the research chemical market is not uniformly regulated, provenance and documentation quality vary widely, and claims should be evaluated against raw data rather than summary labels.
==== Kidnapping and extortion ransoms ==== Colombia is a country in which many people are or have been kidnapped. Kidnapping, as one of the manifestations that underlie armed conflict, carries both direct and indirect costs. The former consists mainly of the payment of ransoms and the expenses assumed by the State to control and prevent kidnapping. Indirect costs include, "[...] the loss of human capital for the duration of the detention and for the death of the kidnapped during his captivity". There are two types of kidnapping:
== Divisions == Roche has two major divisions: Pharmaceuticals and Diagnostics. Roche Diagnostics manufactures diagnostic equipment and reagents for research and medical diagnostic applications. Internally, it is organised into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana). The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland. All business areas except Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers. Applied Science targets research settings in academia and pharmaceutical and biotechnology industries.
The stringed crowns and the trays used in manual sorting are shown in the figure. The destination tray is moved step by step in the direction of the arrow. The crowns are transferred in groups from the slots of the source tray into the all opposite slots of the destination tray. The transfers are directed by computer and the products are identified by the positions of the crowns occupied on the final strings. A fast automatic sorter machine had also been described. The sorter is outlined in the figure. It has two sets of aligned tubes. The lower ones are step by step moving in the direction showed by the arrow and the coin-like units are dropped from the upper source tubes into the lower destination ones. The tubes may serve as reaction vessels too. A software had also been developed that can direct sorting if not a full combinatorial library is synthesized only a set of its components are prepared that are picked out from the full library.
Shooting the elephant to take its tusks: this method is of concern here. Taking tusks from an elephant which has died of natural causes. Taking tusks from an elephant which has had to be put down for another reason, for example, severe arthritis, or if its last molar teeth are worn out and can no longer chew its food. Among working elephants which use their tusks to carry logs, there is an optimal tusk length. In former times, tusks were often cut back to this length (and often the shortened tusks' ends were bound in copper). This periodically freed pieces of ivory for the carving trade.
== Treatment == Treatment for CLSD is largely focused on treating the symptoms of the disorder, because it is still in the early stages of research. Symptomatic treatment is also the only option due to the genetic nature of the disorder. Treatment may include surgeries to correct facial and cranial dysmorphisms or therapy sessions to help alleviate behavioral abnormalities associated with the disorder.
Sources: en.wikipedia.org
=== Cardiovascular === Although cardiovascular involvement depends significantly on the diagnosed subtype of EDS, several co-morbidities and symptoms are closely linked to the disorder as a whole. Some studies suggest that structural abnormalities are not the root cause of the vast majority of cardiac symptoms, but rather, dysautonomia is the primary culprit. Associated symptoms can include, but are not limited to, palpitations, near-syncope and syncope, heat intolerance, and difficulty managing blood pressure and heart rate. One study published in 2013 found that patients with EDS were more likely to also be diagnosed with postural orthostatic tachycardia syndrome, more commonly known as POTS. Weak connective tissues in the heart can cause problems with valve structure and function. Mitral valve prolapse and regurgitation and aortic root dilation are found more commonly in EDS patients and others with similar connective tissue disorders. In some cases, EDS manifests within the vasculature as well. Major artery aneurysms and dissections are sometimes seen as a result of faulty structural integrity.
No flerovium atoms were detected; this was thought to be because the compound nucleus 288Fl only has 174 neutrons instead of the supposed magic 184, and this would have significant impact on the reaction cross section (yield) and half-lives of nuclei produced. It was then 30 more years before flerovium was first made. Later work suggests the islands of stability around hassium and flerovium occur because these nuclei are respectively deformed and oblate, which make them resistant to spontaneous fission, and that the true island of stability for spherical nuclei occurs at around unbibium-306 (122 protons, 184 neutrons). In the 1970s and 1980s, theoretical studies debated whether element 114 would be a more volatile metal like lead, or an inert gas.
Phenformin is an antidiabetic drug from the biguanide class. It was marketed as DBI by Ciba-Geigy, but was withdrawn from most markets in the late 1970s due to a high risk of lactic acidosis, which was fatal in 50% of cases. Phenformin was developed in 1957 by Ungar, Freedman and Seymour Shapiro, working for the U.S. Vitamin Corporation. Clinical trials begun in 1958 showed it to be effective, but with gastrointestinal side effects.
Former Yemeni president Ali Abdullah Saleh had accused the Houthis of having ties to external backers, in particular the Iranian government; Saleh stated in an interview with The New York Times,The real reason they received unofficial support from Iran was because they repeat same slogan that is raised by Iran – death to America, death to Israel. We have another source for such accusations. The Iranian media repeats statements of support for these [Houthi] elements. They are all trying to take revenge against the USA on Yemeni territories. Such backing has been reported by diplomatic correspondents of major news outlets (e.g., Patrick Wintour of The Guardian), and has been the reported perspective of Yemeni governmental leaders militarily and politically opposing Houthi efforts (e.g., as of 2017, the UN-recognized, deposed Yemeni President Abd Rabbu Mansour Hadi, who referred to the "Houthi rebels... as 'Iranian militias'". The Houthis in turn accused the Saleh government of being backed by Saudi Arabia and of using Al-Qaeda to repress them. Under the next President Hadi, Gulf Arab states accused Iran of backing the Houthis financially and militarily, though Iran denied this, and they were themselves backers of President Hadi. Despite confirming statements by Iranian and Yemeni officials in regards to Iranian support in the form of trainers, weaponry, and money, the Houthis denied reception of substantial financial or arm support from Iran.
Sources: en.wikipedia.org
=== Opioid agonist === β-Endorphin is an agonist of the opioid receptors; it preferentially binds to the μ-opioid receptor. Evidence suggests that it serves as a primary endogenous ligand for the μ-opioid receptor, the same receptor to which the chemicals extracted from opium, such as morphine, derive their analgesic properties. β-Endorphin has the highest binding affinity of any endogenous opioid for the μ-opioid receptor. Opioid receptors are a class of G-protein coupled receptors, such that when β-endorphin or another opioid binds, a signaling cascade is induced in the cell. Acetylation of the N-terminus of β-endorphin, however, inactivates the neuropeptide, preventing it from binding to its receptor. The opioid receptors are distributed throughout the central nervous system and within the peripheral tissue of neural and non-neural origin. They are also located in high concentrations in the periaqueductal gray, locus coeruleus, and the rostral ventromedial medulla. In addition to the full-length peptide, brain and pituitary tissue also contain shorter β-endorphin fragments such as β-endorphin(1–27), which can act as a competitive antagonist at μ-opioid receptors and attenuate the analgesic effects of β-endorphin(1–31) in experimental models. Voltage-dependent calcium channels (VDCCs) are important membrane proteins that mediate the depolarization of neurons, and play a major role in promoting the release of neurotransmitters. When endorphin molecules bind to opioid receptors, G proteins activate and dissociate into their constituent Gα and Gβγ sub-units.
==== Concerns ==== An analysis conducted in late 2020 of premarket vaccine purchase commitments indicated that wealthy countries may receive their vaccines in 2020–21 while developing countries may be excluded from vaccinations until 2023–24. Data from April 2021 comports with this expectation since 25% of the population in high income countries have been vaccinated compared to only 0.2% in low income countries. The head of the World Health Organization said on 4 August 2021 that rich countries had administered about 100 doses per 100 people while poor countries had administered only about 1.5 doses for every 100 people, and therefore, in his estimation, it was important to prioritize vaccination in poor countries before offering booster vaccines in rich countries. The WHO Director General Tedros Adhanom Ghedreyesus raised concerns about rich countries hoarding vaccines at the expense of citizens in poorer nations who wait for vaccines to either become available or are donated. The WHO Regional Office of Africa highlighted vaccine discard in African countries, after Nigeria destroyed about 1 million donated doses of AstraZeneca vaccine after being donated with only a few weeks till expiration. Other countries such as Malawi, and South Sudan have either destroyed expired or close to expiring vaccines or paused donated shipments due to expiration concerns.
==== Copycat suicides and romanticisation ==== Another negative effect that misrepresentation of mental illnesses through the news can cause is copycat suicide. As with the deaths of celebrities Kate Spade and Robin Williams, an abundance of media and news coverage occurs. A Columbia University study revealed that "suicides rose nearly 10% higher than expected in the months following Robin Williams' death in August 2014," especially involving the method used by Robin Williams himself (a 32% increase). These results support the idea of suicide contagion, which the U.S. Department of Health & Human Services (HHS) defines as "the exposure to suicide or suicidal behaviors within one's family, one's peer group, or through media reports of suicide and can result in an increase in suicide and suicidal behaviors." A notable mid-2010s case of modern digital media contagion is the 2015 suicide of 16-year-old Russian student Renata Kambolina (known online under the pseudonym Rina Palenkova). After posting a final trackside selfie with the caption "nya. bye." ("ня.пока."), her tragic death rapidly went viral on the Russian social network VKontakte. This sparked a dangerous wave of romanticisation that falsely framed her as a virtual idol, prompting numerous vulnerable youths to replicate either her final words, her exact photo framing, or both, during their own suicides or attempted suicides—notably Gleb Korablyov in 2019. Like Kambolina, Korablyov also had his tragic death immediately seized upon and mythologised by internet trolls and morbid online communities.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.